Oculis announces R&D Retina Day, showcasing global experts in clinical programs


The live streamed event will cover topics including DME, CME, AON and more.

A group of researchers examine test tubes in a laboratory. Image credit: ©alphaspirit – stock.adobe.com

A panel of experts will answer questions about DME, CME, AON and more. Image credit: ©alphaspirit – stock.adobe.com

In July, biopharmaceutical company Oculis Holding AG will hold its first R&D Day to highlight its clinical developments in retina care. In a press release, the company, headquartered in Switzerland, announced a live event in New York City which will also be broadcast online.1 The in-person and online showcase will be held Tuesday, 11 July, from 10AM to 12PM EDT.

Retina specialists will participate in presentations and a panel discussion. Topics that appear on the day's agenda include Diabetic Macular Edema (DME), Cystoid Macular Edema (CME) and Acute Optic Neuritis (AON).1 The news release also included details of the clinical programming Oculis will showcase during the event, which include:

  • OCS-01 DME DIAMOND programme: The recent Stage 1 read-out of the DIAMOND trial and plans for the upcoming DIAMOND 1 and DIAMOND 2 trials1
  • OCS-01 CME LEOPARD trial: The PoC LEOPARD trial initiation of OCS-01 eye drops in CME1
  • OCS-05 AON ACUITY trial: The ongoing PoC ACUITY trial of OCS-05, a neuroprotective candidate with a novel mechanism of action, in Acute Optic Neuritis1

Oculis also released a list of specialists and researchers who will participate in the day’s events. Presenters expected to appear include Sophie Bonnin, MD, neuro-retina specialist at the Foundation Rothschild Hospital, Paris; David S. Boyer, MD, University of Southern California Keck School of Medicine; Quan Dong Nguyen, MD, MSc, FARVO, FASRS, Byers Eye Institute, Stanford University School of Medicine; and Arshad M. Khanani, MD, MA, FASRS, University of Nevada, Reno School of Medicine.

Panelists in the Q&A session will include Pravin Dugel, MD, president of Iveric Bio; Sabri Markabi, MD, an independent R&D consultant; Ramin Tadayoni, MD, professor of ophthalmology at University of Paris; and Pablo Villoslada, MD, adjunct professor at Stanford University. Oculis CEO, Riad Sherif, MD, will lead the discussion; Bastian Dehmel, MD, head of development at Oculis, will also answer questions.

Registration is free through the Oculis website. The in-person event takes place at the Lotte New York Palace Hotel. The registration page includes a submission form so attendees may ask the panelists questions.


  1. Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023. News release. Oculis SA, June 26, 2023. https://www.globenewswire.com/news-release/2023/06/26/2694396/0/en/Oculis-to-Host-an-R-D-Retina-Day-to-Showcase-Clinical-Programs-Targeting-Diabetic-Macular-Edema-and-Other-Retina-Diseases-on-Tuesday-July-11-2023.html
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.